In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment DOI
Prabhanjan S. Giram, Kazi Md Mahabubur Rahman,

Osama Aqel

и другие.

ACS Biomaterials Science & Engineering, Год журнала: 2025, Номер unknown

Опубликована: Апрель 14, 2025

Cancer is one of the leading causes mortality worldwide. Nanomedicines have significantly improved life expectancy and survival rates for cancer patients in current standard care. However, recurrence due to metastasis remains a significant challenge. Vaccines can provide long-term protection are ideal preventing bacterial viral infections. vaccines, however, shown limited therapeutic efficacy raised safety concerns despite extensive research. vaccines target stimulate responses against tumor-specific antigens demonstrated great potential treatment preclinical studies. tumor-associated immunosuppression immune tolerance driven by immunoediting pose challenges vaccine design. In situ vaccination represents an alternative approach traditional vaccines. This strategy involves intratumoral administration immunostimulants modulate growth differentiation innate cells, such as dendritic macrophages, neutrophils, restore T-cell activity. Currently approved T-VEC, clinical promise, while ongoing trials continue explore novel strategies broader efficacy. Despite these advancements, failures research highlight need address suppression escape mechanisms. combine adaptive stimulation, leveraging activate cells cross-prime CD8+ T cells. Various modalities, nucleotide-based (e.g., RNA DNA vaccines), peptide-based cell-based (including dendritic, T-cell, B-cell approaches), show potential. Plant-based approaches, including cowpea mosaic virus Newcastle disease virus, further expand toolkit vaccination. Therapeutic modalities chemotherapy, radiation, photodynamic therapy, photothermal Checkpoint blockade inhibitors contribute enhanced antigen presentation activation. Adjuvants like CpG-ODN PRR agonists enhance modulation The advantages include patient specificity, personalization, minimized escape, reduced logistical costs. barriers tumor heterogeneity, evasion, remain. review explores developing potent examines trials, evaluates stimulation methods, discusses prospects advancing

Язык: Английский

Redefining Hepatocellular Carcinoma Treatment: Nanotechnology Meets Tumor Immune Microenvironment DOI
Chen Mi, Sai Liu, Zhida Chen

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 47

Опубликована: Март 13, 2025

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, conventional chemotherapy, five-year survival rate for this neoplasm remains dismally low. The progress nanotechnology has revolutionized cancer treatment years. These provide unprecedented opportunities to overcome current limitations different modalities. This review provides a comprehensive analysis how interfaces with tumor microenvironment (TIME) HCC can present new frontier interventions HCC. We critically overview latest developments nanoparticle-based delivery systems various drugs also other antitumor agents like thermal therapy radiotherapy. highlight unique ability nanoparticles modulate immunosuppressive (TME) enhance efficacy. Furthermore, we analyze emerging strategies that exploit nanoformulations biological barriers drug bioavailability treatment.

Язык: Английский

Процитировано

0
In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment DOI
Prabhanjan S. Giram, Kazi Md Mahabubur Rahman,

Osama Aqel

и другие.

ACS Biomaterials Science & Engineering, Год журнала: 2025, Номер unknown

Опубликована: Апрель 14, 2025

Cancer is one of the leading causes mortality worldwide. Nanomedicines have significantly improved life expectancy and survival rates for cancer patients in current standard care. However, recurrence due to metastasis remains a significant challenge. Vaccines can provide long-term protection are ideal preventing bacterial viral infections. vaccines, however, shown limited therapeutic efficacy raised safety concerns despite extensive research. vaccines target stimulate responses against tumor-specific antigens demonstrated great potential treatment preclinical studies. tumor-associated immunosuppression immune tolerance driven by immunoediting pose challenges vaccine design. In situ vaccination represents an alternative approach traditional vaccines. This strategy involves intratumoral administration immunostimulants modulate growth differentiation innate cells, such as dendritic macrophages, neutrophils, restore T-cell activity. Currently approved T-VEC, clinical promise, while ongoing trials continue explore novel strategies broader efficacy. Despite these advancements, failures research highlight need address suppression escape mechanisms. combine adaptive stimulation, leveraging activate cells cross-prime CD8+ T cells. Various modalities, nucleotide-based (e.g., RNA DNA vaccines), peptide-based cell-based (including dendritic, T-cell, B-cell approaches), show potential. Plant-based approaches, including cowpea mosaic virus Newcastle disease virus, further expand toolkit vaccination. Therapeutic modalities chemotherapy, radiation, photodynamic therapy, photothermal Checkpoint blockade inhibitors contribute enhanced antigen presentation activation. Adjuvants like CpG-ODN PRR agonists enhance modulation The advantages include patient specificity, personalization, minimized escape, reduced logistical costs. barriers tumor heterogeneity, evasion, remain. review explores developing potent examines trials, evaluates stimulation methods, discusses prospects advancing

Язык: Английский

Процитировано

0